A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults

Completed · Phase 1 · Has a placebo group

Conditions studied: Multiple Sclerosis

In brief

This study will evaluate the safety, tolerability, and pharmacokinetics of ALKS 8700, a monomethyl fumerate (MMF) molecule.

Key facts

Study ID

NCT02201849

Run by

Biogen

People needed

104

Starts

2014-07-01

Expected to finish

2014-12-01

Last updated by the study team

2019-11-26

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Has a body-mass Index (BMI) >/=18.0 and </=32.0 kg/m2
• Agrees to use an acceptable method of contraception for the duration of the study and for 30 days after any study drug administration
• Additional criteria may apply

You may not qualify if…

• Is currently pregnant or breastfeeding
• Has a lifetime history of menopausal hot flashes
• Has a clinically significant medical condition
• Has had a clinically significant illness in the 30 days prior to first study drug administration
• Has had a serious infection (eg, pneumonia or septicemia) within the 3 months prior to study drug administration
• Has had any vaccinations in the 4 weeks prior to inpatient admission
• Has a lifetime history of diabetes
• Additional criteria may apply

Where it is running

• Alkermes Investigational Site — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.